John Su to Adolescent
This is a "connection" page, showing publications John Su has written about Adolescent.
Connection Strength
0.097
-
Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016. J Allergy Clin Immunol. 2019 04; 143(4):1465-1473.
Score: 0.022
-
Safety of Second-Dose Single-Antigen Varicella Vaccine. Pediatrics. 2017 Mar; 139(3).
Score: 0.019
-
COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 06; 70(31):1053-1058.
Score: 0.007
-
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 09; 70(27):977-982.
Score: 0.007
-
US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. JAMA. 2021 06 22; 325(24):2448-2456.
Score: 0.007
-
Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021. MMWR Morb Mortal Wkly Rep. 2021 May 07; 70(18):685-688.
Score: 0.006
-
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021 May 07; 70(18):680-684.
Score: 0.006
-
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 30; 70(17):651-656.
Score: 0.006
-
First Month of COVID-19 Vaccine Safety Monitoring - United States, December 14, 2020-January 13, 2021. MMWR Morb Mortal Wkly Rep. 2021 Feb 26; 70(8):283-288.
Score: 0.006
-
Reported Primary and Secondary Syphilis Cases in the United States: Implications for HIV Infection. Sex Transm Dis. 2018 09; 45(9S Suppl 1):S42-S47.
Score: 0.005
-
Age at onset and persistence of eczema are related to subsequent risk of asthma and hay fever from birth to 18 years of age. Pediatr Allergy Immunol. 2017 06; 28(4):384-390.
Score: 0.005